-transparent.png){kind=logo}
Clonal chromosome abnormalities were observed in 30 patients with non-Hodgkin's lymphoma; the type of lymphoma was characterized on the basis of the International Working Formulation. The 30 patients were classified into five groups according to the chromosome abnormality. There were 8 patients with t(14;18), 3 with t(8;14), 7 with a translocation to the long arm of chromosome 3 (a 3q+ chromosome), 5 with near-tetraploidy, and 7 with other abnormalities. Among the 8 patients with t(14;18), 5 had follicular small cleaved-cell lymphoma (FSC), I had follicular mixed cell lymphoma (FM), and 2 had diffuse large-cell lymphoma (DL); the diagnosis in these 2 patients was based on extranodal tissue. All 3 patients with t(8;14) had DL and B-cell markers. Except for 1 patient, all those with a 3q+ chromosome had DL; 4 of those who were tested had B-cell or pre-B-cell markers. Four of the 5 patients with near-tetraploidy had follicular mixed-cell lymphoma, and 2 of the 7 patients with other abnormalities had T-cell lymphoma. Thus, patients with a t(8;14), a 14q+ chromosome, or a 3q+ chromosome all tend to have diffuse large-cell lymphoma, usually of the non-cleaved type. On the other hand, our data suggest that patients with FSC generally have a t(14;18) whereas those with follicular and diffuse mixed small cleaved cells and large noncleaved cells have a different pattern with modal chromosome numbers in the tetraploid range. We added 17 previously reported patients to the 30 presented here and correlated the karyotype with survival. The 6 patients with near-tetraploidy had the longest median survival, 69 months, the 15 patients with t(14;18) had the next longest, 48 months. The 4 patients with t(8;14) had the shortest survival, 12 months, and the 9 with other abnormalities had the next shortest, 17 months. Intermediate survivals of 27 and 30 months were observed in patients with a 14q+ or a 3q+ chromosome, respectively. The median survival of these various categories differs and our data, thus, indicate that the karyotypic pattern of the malignant cell may be a significant independent prognostic feature influencing the survival of patients with non-Hodgkin's lymphoma.
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
March 1986,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
August 1996,
European journal of cancer (Oxford, England : 1990),
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
June 1986,
Blood,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
April 1986,
International journal of radiation oncology, biology, physics,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
October 1990,
Current opinion in oncology,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
October 1992,
Current opinion in oncology,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
September 2002,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
October 2002,
European journal of haematology,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
May 1999,
Leukemia,
Y Kaneko, and
J D Rowley, and
D Variakojis, and
J M Haren, and
Y Ueshima, and
K Daly, and
L F Kluskens
June 2005,
Leukemia,
